Get Level 2

SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Rtw Biotech Share Price
  4. Rtw Biotech Share Regulatory News
  5. Spectris

Pin to quick picksRtw Biotech Regulatory News (RTW)

Rtw Biotech Information

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Spectris

1 Dec 2025 18:00

RNS Number : 7232J
FTSE Russell
01 December 2025
 

 

 

Further to the FTSE Russell notice released on 25 November 2025 in relation to Spectris (UK): Constituent Deletion, please note the FTSE 250 Index replacement and associated changes.

 

All other details remain unchanged. Please see updated notice below:

Spectris (UK): Constituent Deletion - UpdateChanges in FTSE UK Index Series

01 December 2025

Subject to court sanctioning the scheme of arrangement for the cash offer for Spectris (UK, constituent) by Aurora Bidco Limited (non-constituent), please see details of affected indexes and effective dates below:

 

Spectris (UK, 0330860) will be deleted from the FTSE 250 Index.

 

RTW Biotech Opportunities (UK, BKTRRM2) will be added to the FTSE 250 Index and deleted from the FTSE SmallCap Index.

 

All changes effective from the open of Thursday 04 December 2025.

 

Full details of changes are available on the FTSE Russell website.

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+61 (0) 2 7228 5659

Hong Kong

+852 2164 3333

Japan

+81 3 6441 1430

London

+44 (0) 20 7866 1810

New York

+1877 503 6437

Alternatively please visit our website at lseg.com/ftse-russell

Terms of Use | Copyright © 2025 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FTSTBBJTMTMMBIA
234567891011
Date   Source Headline
14th Sep 20237:00 amRNSUpdate on Largest Core Portfolio Position
13th Sep 20237:00 amRNSHalf-year Report
6th Sep 20237:00 amRNSTransaction in Own Shares
4th Sep 202311:00 amRNSAdditional Investment in Portfolio Company
14th Aug 20237:00 amRNSMonthly Valuation Update & July Factsheet
4th Aug 20237:30 amRNSEdison issues update on RTW Venture Fund (RTW)
1st Aug 202312:30 pmRNSTotal Voting Rights
21st Jul 20237:00 amRNSTransaction in Own Shares
17th Jul 20237:00 amRNSPortfolio Company Update: Apogee Therapeutics IPO
17th Jul 20237:00 amRNSMonthly Valuation Update, Factsheet & Q2 Letter
5th Jul 20237:00 amRNSCapital Allocation Plans from Prometheus Sale
30th Jun 202310:00 amRNSPortfolio Company Update: Tourmaline Bio
27th Jun 20237:00 amRNSChange of Name
21st Jun 20234:22 pmRNSResult of AGM
14th Jun 20237:00 amRNSMonthly Valuation Update & Factsheet
1st Jun 20237:00 amRNSNotice of AGM
12th May 20237:00 amRNSMonthly Valuation Update & Factsheet
9th May 20237:00 amRNSPortfolio Company Update: Acelyrin IPO
2nd May 20237:00 amRNSAnnual Financial Report
26th Apr 20237:00 amRNSNew Investment in Abdera Therapeutics
24th Apr 20232:39 pmRNSMarch Factsheet & First Quarter Letter
17th Apr 20237:00 amRNSPortfolio Company Update: Prometheus Biosciences
17th Apr 20237:00 amRNSMonthly Valuation Update
6th Apr 202312:00 pmRNSAppointment of Numis as Joint Broker
31st Mar 20235:20 pmRNSDirector/PDMR Shareholding
31st Mar 20237:00 amRNSAnnual Financial Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 202310:47 amRNSPortfolio Company Update: Strategic Financing
16th Mar 20234:00 pmRNSDirector Declaration
14th Mar 20237:00 amRNSMonthly Valuation Update
13th Mar 20233:20 pmRNSUpdate re Silicon Valley Bank exposure
1st Mar 20232:45 pmRNSNew Investment in Cargo Therapeutics
1st Mar 202310:00 amRNSNew Investment in Oricell Therapeutics
14th Feb 20237:00 amRNSMonthly Valuation Update
13th Feb 20234:51 pmRNSPortfolio Company Update
26th Jan 202311:32 amRNSQuotedData's Weekly News & Interview
25th Jan 20237:00 amRNSQuarterly Update
20th Jan 20234:29 pmRNSUpdate research from QuotedData
16th Jan 20237:00 amRNSNet Asset Value(s)
22nd Dec 20224:23 pmRNSDirector/PDMR Shareholding
19th Dec 202211:17 amRNSResult of General Meeting
14th Dec 20227:00 amRNSNet Asset Value(s)
13th Dec 202210:01 amRNSEdison issues flash on RTW Venture Fund (RTW)
8th Dec 20225:57 pmRNSMaterial Update from Portfolio Company
7th Dec 20221:00 pmRNSNew Investment in Apogee Therapeutics
1st Dec 20227:00 amRNSPublication of Circular & Convening of EGM
30th Nov 20222:00 pmRNSDirector/PDMR Shareholding
28th Nov 20227:00 amRNSChange of status for US federal tax - PTP to PFIC
14th Nov 20227:00 amRNSNet Asset Value(s)
4th Nov 20224:04 pmRNSDirector/PDMR Shareholding
234567891011

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
GB67
Barclays 28
LSE
0.00%
TEAM
Team
LSE
0.00%
LD94
Citi Fun 27
LSE
0.00%
RF46
Mort.bt 22-1.54
LSE
0.00%
OB39
Citi Fun 27
LSE
0.00%
Trending
NRGB.PL
Energy B Plc
AQSE
127.27%
CPX
CAP-XX
LSE
-1.82%
ITV
ITV
LSE
0.79%
HUI
Hydrogen Utopia
LSE
0.00%
KOD
Kodal Minerals
LSE
0.00%